Latest Organogenesis Inc. Stories
Data Represents the Largest Real World Comparative Effectiveness Analysis Conducted with Apligraf CANTON, Mass., May 6, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today key findings demonstrating the speed and incidence of wound closure for venous leg ulcer (VLU) patients who were treated with Apligraf®. The oral presentation of the abstract, titled "A Retrospective Analysis of a Bilayered Living Cellular Construct...
Six Presentations Accepted at SAWC/WHS to Highlight Scientific Characteristics of Apligraf®, Real World Effectiveness in VLU Patients and Economic Burden of DFUs and VLUs CANTON, Mass., April 30, 2013 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it will present new Apligraf® comparative effectiveness data and chronic wound burden of illness economic analyses at the Symposium of Advanced Wound Care (SAWC) and...
CANTON, Mass., Aug. 6, 2012 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, is announcing Symone Isaac-Wilkins as the winner of its annual college scholarship. The award honors the achievement of a graduating Canton High School senior interested in pursuing a career in medicine, life sciences research or biomedical engineering. (Photo: http://photos.prnewswire.com/prnh/20120806/NE52040) Symone, who graduated among the top in her class...
CANTON, Mass., April 17, 2012 /PRNewswire/ -- Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that Apligraf® has established improved coverage from multiple payors, improving access to care for millions of patients suffering from chronic, non-healing wounds. Apligraf is the only cell-based product with FDA approval for the treatment of both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). National Government Services, one of the...
CANTON, Mass., March 27, 2012 /PRNewswire/ -- Today MassBio members elected Geoff MacKay, president & CEO of regenerative medicine leader Organogenesis Inc., as chairman of the board of directors at the 2012 MassBio Annual Meeting. (Photo: http://photos.prnewswire.com/prnh/20120327/NE76866) During this year's meeting, MassBio members also elected three new board members: Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of...
CANTON, Mass., March 12, 2012 /PRNewswire/ -- Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT(TM) (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue). The GINTUIT approval marks two important firsts: the first-ever...
CANTON, Mass., April 13, 2011 /PRNewswire/ -- Today Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister joined state and local officials, Organogenesis, Inc. President & CEO Geoff MacKay and employees to celebrate the start of construction of 275 Dan Road. Upon completion in 2013, the company expects the facility to be the world's largest automated living cell manufacturing plant. Organogenesis is in the midst of a major, multi-year expansion of its global...
CANTON, Mass., Nov. 10, 2010 /PRNewswire/ -- Organogenesis, Inc. announced today that Apligraf®, the only product with FDA approval for the treatment of both diabetic foot ulcers and venous leg ulcers, will have two new procedure codes assigned by the Centers for Medicare & Medicaid Services (CMS) as of January 2011. The new codes will enable physicians to receive appropriate reimbursement for each application of Apligraf in accordance with its FDA labeling criteria, which includes...
CANTON, Mass., Sept. 28 /PRNewswire/ -- Organogenesis, Inc. announced that its Apligraf® bilayered living cellular construct has been approved for the treatment of diabetic foot ulcers and other chronic wounds by the Saudi Food and Drug Authority (SFDA) of the Kingdom of Saudi Arabia. Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the U.S. and around the world. "With diabetes being a widespread and growing medical problem in Saudi Arabia...
CANTON, Mass., Sept. 28 /PRNewswire/ -- Today Governor Deval Patrick and Massachusetts Life Sciences Center President & CEO Susan Windham-Bannister, joined state and local officials, Organogenesis, Inc. CEO Geoff MacKay and employees, to celebrate the completion of the company's new headquarters building at 85 Dan Road in Canton. Organogenesis kicked off the celebration by announcing that its Apligraf® living cell based product has been approved for the treatment of diabetic foot...
